SCHEMBL6714588

SCHEMBL6714588

CCOC(Cc1ccc(OCCOC2c3ccc(-c4ccccc4)cc3C=Cc3ccc(CC)cc32)cc1)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 19/20 0.51
PPARG P37231 17/20 0.51
PPARD Q03181 12/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6716230 0.97 PPARA (0.50) PPARAPPARGPPARD
SCHEMBL6716247 0.96 PPARA (0.53) PPARAPPARGPPARD
SCHEMBL6719693 0.96 PPARA (0.53) PPARAPPARGPPARD
SCHEMBL6717643 0.94 PPARA (0.56) PPARAPPARGPPARD
SCHEMBL6724141 0.94 PPARA (0.49) PPARAPPARGPPARD
SCHEMBL6716365 0.94 PPARA (0.49) PPARAPPARGPPARD
SCHEMBL6714504 0.94 PPARA (0.43) PPARAPPARGPPARD
SCHEMBL6724415 0.93 PPARA (0.56) PPARAPPARGPPARD
SCHEMBL6717227 0.93 PPARA (0.55) PPARAPPARGPPARD
SCHEMBL6715620 0.93 PPARA (0.51) PPARAPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010031764-A1 Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors(PPAR) JEPPESEN LONE (DK) 2001-10-18 US claimed
US-20010031762-A1 Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) JEPPESEN LONE (DK) 2001-10-18 US claimed
US-20010031786-A1 Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) JEPPESEN LONE (DK) 2001-10-18 US claimed
EP-1123269-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2001-08-16 EP claimed
US-6248781-B1 ANTIDIABETIC AGENTS; DIETETICS NOVO NORDISK A/S (DK) 2001-06-19 US claimed
WO-2000023417-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-04-27 WO claimed
US-20040229899-A1 Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) JEPPESEN LONE (DK) 2004-11-18 US disclosed
US-6723731-B2 3-(4-(2-(5H-DIBENZO(A,D)CYCLOHEPTEN-5-YLOXY)-ETHOXYL-PHENYL)-2 -ETHOXY-PROPIONIC ACID ETHYL ESTER AS ANTIDIABETIC AGENTS AND TO TREAT OBESITY NOVO NORDISK A/S (DK) 2004-04-20 US disclosed
US-6602901-B2 Antidiabetic agents, obesity NOVO NORDISK A/S (DK) 2003-08-05 US disclosed
US-6407127-B2 3-(4-(2-(5H-DIBENZO(A,D)CYCLOHEPTEN-5-YLOXY)-ETHOXYL-PHENYL)-2 -ETHOXY-PROPIONIC ACID ETHYL ESTER AS ANTIDIABETIC AGENTS AND TO TREAT OBESITY NOVO NORDISK A/S (DK) 2002-06-18 US disclosed
US-20010031764-A1 Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors(PPAR) JEPPESEN LONE (DK) 2001-10-18 US disclosed
US-20010031762-A1 Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) JEPPESEN LONE (DK) 2001-10-18 US disclosed
US-20010031786-A1 Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) JEPPESEN LONE (DK) 2001-10-18 US disclosed
EP-1123269-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2001-08-16 EP disclosed
US-6248781-B1 ANTIDIABETIC AGENTS; DIETETICS NOVO NORDISK A/S (DK) 2001-06-19 US disclosed
WO-2000023417-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031762-A1 Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) PPARG, PPARA, PPARD PPARA 2/4885PPARG 1/4885PPARD 3/4885
US-20010031786-A1 Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) PPARG, PPARA, PPARD PPARA 2/4885PPARG 1/4885PPARD 3/4885
US-20010031764-A1 Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors(PPAR) PPARG, PPARA, PPARD PPARA 2/4885PPARG 1/4885PPARD 3/4885
US-20040229899-A1 Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) PPARG, PPARA, PPARD PPARA 2/4885PPARG 1/4885PPARD 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.